Abstract
Glutathione (GSH) is the most abundant antioxidant in aerobic cells, present in micromolar (μM) concentrations in bodily fluids and in millimolar (mM) concentrations in tissue. GSH is critical for protecting the brain from oxidative stress, acting as a free radical scavenger and inhibitor of lipid peroxidation. GSH also participates in the detoxification of hydrogen peroxide by various glutathione peroxidases. The ratio of reduced GSH to oxidized GSH (GSSG) is an indicator of cellular health, with reduced GSH constituting up to 98% of cellular GSH under normal conditions. However, the GSH/GSSG ratio is reduced in neurodegenerative diseases, such as Parkinson’s disease (PD) and Alzheimer’s disease (AD). Measuring the GSH/GSSG ratio in pathological tissues and experimental models thereof in comparison to the results in controls is an excellent way to assess potential therapeutics efficacy in maintaining cellular redox potential. The availability of UV/Visible instruments equipped with 96-well plate readers as common laboratory equipment has made measuring the GSH/GSSG ratio on multiple samples a manageable procedure.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Janaky R, Cruz-Aguado R, Oja SS, Shaw CA (2007) Glutathione in the nervous system: roles in neural function and health and implications for neurological disease. In: Lajtha A, Oja SS, Saransaari P, Schousboe A (eds) Handbook of neurochemistry and molecular neurobiology. Amino acids and peptides in the nervous system, 3rd edn. Springer, New York, pp 349–418
Slivka A, Spina MB, Cohen G (1987) Reduced and oxidized glutathione in human and monkey brain. Neurosci Lett 74:112–118
Kosower NS, Kosower EM (1978) The glutathione status of cells. Int Rev Cytol 54:109–160
Lovell MA, Ehmann WD, Butler SM, Markesbery WR (1995) Elevated thiobarbituric acid-reactive substances and antioxidant enzyme activity in the brain in Alzheimer’s disease. Neurology 45:1594–1601
Sofic E, Lange KW, Jellinger K, Riederer P (1992) Reduced and oxidized glutathione in the substantia nigra of patients with Parkinson’s disease. Neurosci Lett 142:128–130
Adams JD Jr, Wang B, Klaidman LK, LeBel CP, Odunze IN, Shah D (1993) New aspects of brain oxidative stress induced by tert-butylhydroperoxide. Free Radic Biol Med 15:195–202
Sultana R, Piroddi M, Galli F, Butterfield DA (2008) Protein levels and activity of some antioxidant enzymes in hippocampus of subjects with amnestic mild cognitive impairment. Neurochem Res 33:2540–2546
Ansari MA, Joshi G, Huang Q, Opii WO, Abdul HM, Sultana R, Butterfield DA (2006) In vivo administration of D609 leads to protection of subsequently isolated gerbil brain mitochondria subjected to in vitro oxidative stress induced by amyloid beta-peptide and other oxidative stressors: relevance to Alzheimer’s disease and other oxidative stress-related neurodegenerative disorders. Free Radic Biol Med 41:1694–1703
Boyd-Kimball D, Sultana R, Abdul HM, Butterfield DA (2005) Gamma-glutamylcysteine ethyl ester-induced up-regulation of glutathione protects neurons against Abeta(1-42)-mediated oxidative stress and neurotoxicity: implica-tions for Alzheimer’s disease. J Neurosci Res 79:700–706
Joshi G, Hardas S, Sultana R, St Clair DK, Vore M, Butterfield DA (2007) Glutathione elevation by gamma-glutamyl cysteine ethyl ester as a potential therapeutic strategy for preventing oxidative stress in brain mediated by in vivo administration of adriamycin: implication for chemobrain. J Neurosci Res 85:497–503
Reed TT, Owen J, Pierce WM, Sebastian A, Sullivan PG, Butterfield DA (2009) Proteomic identification of nitrated brain proteins in traumatic brain-injured rats treated postinjury with gamma-glutamylcysteine ethyl ester: insights into the role of elevation of glutathione as a potential therapeutic strategy for traumatic brain injury. J Neurosci Res 87:408–417
Sultana R, Newman SF, Abdul HM, Cai J, Pierce WM, Klein JB, Merchant M, Butterfield DA (2006) Protective effect of D609 against amyloid-beta1-42-induced oxidative modification of neuronal proteins: redox proteomics study. J Neurosci Res 84:409–417
Butterfield DA, Pocernich CB, Drake J (2002) Elevated glutathione as a therapeutic strat-egy in Alzheimer’s disease. Drug Dev Res 56:428–437
Kemp M, Go YM, Jones DP (2008) Nonequilibrium thermodynamics of thiol/disulfide redox systems: a perspective on redox systems biology. Free Radic Biol Med 44:921–937
Anderson, ME (1996) Glutathione in Free Radicals: a practical approach (Punchard, N, Kelly, FJ, ed.) Oxford University Press, New York, NY, pp 213–226
Baker MA, Cerniglia GJ, Zaman A (1990) Microtiter plate assay for the measurement of glutathione and glutathione disulfide in large numbers of biological samples. Anal Biochem 190:360–365
Griffith OW (1980) Determination of glutathione and glutathione disulfide using glutathione reductase and 2-vinylpyridine. Anal Biochem 106:207–212
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2010 Springer Science+Business Media, LLC
About this protocol
Cite this protocol
Owen, J.B., Butterfield, D.A. (2010). Measurement of Oxidized/Reduced Glutathione Ratio. In: Bross, P., Gregersen, N. (eds) Protein Misfolding and Cellular Stress in Disease and Aging. Methods in Molecular Biology, vol 648. Humana Press, Totowa, NJ. https://doi.org/10.1007/978-1-60761-756-3_18
Download citation
DOI: https://doi.org/10.1007/978-1-60761-756-3_18
Published:
Publisher Name: Humana Press, Totowa, NJ
Print ISBN: 978-1-60761-755-6
Online ISBN: 978-1-60761-756-3
eBook Packages: Springer Protocols